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A case of a 23-year-old woman with a paraovarian tumor is presented.
The patient complained of pelvic pain and abdominal swelling. Cystect-
omy was the initial surgical treatment, but after the histological diag-
nosis, a staging surgery was carried out. The clinical aspects and
subsequent management of related cases are discussed, and a literature
review is made.
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Case report
A23-year-old Caucasianwoman attended her gynecolo-
gist complaining of sudden abdominal enlargement
and pelvic pain. Pelvic examination revealed an
8 8 cm mass occupying the right adnexa; it was a
painful, mobile mass, with a hard-elastic consistency.
Ultrasound investigation revealed, above the uterus,
an unilocular cystic mass measuring 118 102
100mm. This cystic formation was avascular and had
avascular vegetations. Preoperative investigations (cell
blood count, biochemistry, electrocardiogram, chest
X-ray, and CA-125) were normal. At laparotomy, the
right paraovarium contained a large homogeneous
cystic mass, measuring 16 16 cm, which was
removed. Because abdominal and pelvic examination
was normal, no further resection was made. Histo-
logically, the cyst wall was covered by simple cuboidal
epithelium without any secretory activity. There were
papillary ingrowths whose fibrovascular axis was
lined by cuboidal epithelium, sometimes with nuclear
stratification and irregular boundaries; focally, micro-
papilla could be seen. There was no stromal invasion
nor invasion of the fibrovascular axis. The cyst was
identified as paramesonephric in its origin.
The lesion was classified as a borderline serous
cystadenocarcinoma arising from a paraovarian cyst
(Fig. 1).
As so, the patient was submitted to a staging lapar-
otomy: multiple biopsies (peritoneal biopsies from
cul-de-sac, sigmoid and bladder serosa, right and
left pelvic sidewalls, right and left paracolic gutters,
right and left diaphragms, and from both ovaries),
and peritoneal washings were taken.
The final histology revealed that peritoneal wash-
ings and multiple biopsies were negative for malig-
nancy, staging the case as IA (FIGO).
The postoperative course was uneventful. The
patient has been regularly followed, and there is no
clinical evidence of disease, 5 months after diagnosis.
Discussion
Borderline epithelial ovarian tumors represent
15—25% of all epithelial ovarian cancers. Borderline
tumors have a biological behavior between benignity
and frank malignancy(1).
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Paraovarian cysts develop in the mesosalpinx
between the ovarian hilus and the fallopian tube.
Their origin may be mesothelial, mesonephric, or,
more commonly, paramesonephric (Mullerian)(1).
There seems to be a relationship between prenatal
diethylstilbestrol exposure and histological anomalies
in paraovarian cysts(2).
Most tumors developed from paraovarian cysts
are benign serous tumors(1). Primary malignant para-
ovarian epithelial tumors (PETs) are rare with only
35 cases described in the literature, and of these,
26 were cystadenocarcinomas with low malignant
potential(3,6—11).
PETs mostly occur in young women (91% during
fertile age). Abdominal enlargement and pelvic pain
are the usual complaints(3). Usually, they have a
capsule, are unilateral, and are connected to the
broad ligament. Ultrasound studies reveal a mutilo-
culated cystic mass that, in histology, has thin walls
with multiple internal papillary projections(3).
A retrospective study published in 1990 concluded
that the diagnosis was never made before surgery
(only histology was conclusive); all women were sub-
mitted to surgical re-intervention and 10% coexisted
with pregnancy. As we are dealing with women
who wish to preserve their fertility, treatment is
controversial(3).
Most authors defend that borderline PETs should
be handled like their ovarian counterparts with
staging surgery associated with conservative or more
aggressive surgery according to rigid clinical and
histological criteria. Conservative surgery consists of
cystectomy, oophorectomy, or anexectomy(1).
The criteria for conservative surgery are lack
of external vegetations, lack of adhesions, tumor
excision without rupture, no ascitis, no other
structures involved, low-grade malignancy, and whish
to maintain fertility. Nonetheless, if one of these criteria
is not accomplished or fertility is not wanted, more
aggressive surgery is advised (total abdominal hyster-
ectomyþ bilateral adenectomyþmultiple biopsiesþ
omentectomy)(1). The absence of free surgical margins
and the removal of several cysts have been asso-
ciated with persistence or recurrence of the tumor(4).
Borderline ovarian tumors are associated with
peritoneal implants in 15—40% of the cases(5). There-
fore, it is essential that we make sure that the disease
has not spread, submitting patients to staging
laparotomy(1).
Because the entity is rare, there is no standardized
follow-up strategy. Although never reported, some
authors defend that these tumors may behave like
their ovarian counterparts having late recurrences(1,3).
Conclusions
Primary PETs are rare, and only 35 cases have been
documented in the literature. These tumors occur
mostly in young women, which makes it difficult to
have a standard treatment.
Many authors have accepted that paraovarian bor-
derline tumors behave like their ovarian counterparts.
Hence, we recommend the same management to
these tumors, obeying to rigid clinical and histological
criteria.
Paraovarian borderline tumors seem to have a good
prognosis; but as they can have late recurrences, we
recommend a tight follow-up.
The treatment of borderline PET should be indivi-
dualized.
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